Patients’ preferences for treatment outcomes for advanced non-small cell lung cancer: A conjoint analysis

Bridges, John F.P.; Mohamed, Ateesha F.; Finnern, Henrik W.; Woehl, Anette; Hauber, A. Brett

doi:10.1016/j.lungcan.2012.01.016

Cited by 122 publications

(117 citation statements)

References 43 publications

Supporting

Mentioning

114

Contrasting

Order By: Relevance

“…Stated preference methods such as the DCE have been commonly used in health care and health economics [39][40][41][42]. The DCE is an (multi)attributebased survey method for analyzing latent preference structures and measuring utilities in order to gain information on assessment and forecast of demand and acceptance of healthcare products or services.…”

Section: Study and Survey Designmentioning

confidence: 99%

Incentives for Blood Donation: A Discrete Choice Experiment to Analyze Extrinsic Motivation

Sadler

Shi

Bethge

et al. 2018

Transfus Med Hemother

View full text Add to dashboard Cite

Background: Demographic trends affect size and age structure of populations. One of the consequences will be an increasing need for blood products to treat age-related diseases. Donation services rely on voluntariness and charitable motivation. It might be questioned whether there will be sufficient blood supply with voluntary donation. The present study focused on elicitation of preferences for incentives and aimed to contribute to the discussion on how to increase donation rates. Methods: A self-administered discrete choice experiment (DCE) was applied. Respondents were repeatedly asked to choose between hypothetical blood donation centers. In case of reluctance to receiving incentives a none-option was included. Random parameter logit (RPL) and latent class models (LCM) were used for analysis. Results: The study sample included 416 college students from the US and Germany. Choice decisions were significantly influenced by the characteristics of the donation center in the DCE. Incentives most preferred were monetary compensation, paid leave, and blood screening test. LCM identified subgroups with preference heterogeneity. Small subgroups indicated moderate to strong aversion to incentives. Conclusion: The majority of the sample positively responded to incentives and indicated a willingness to accept incentives. In face of future challenges, the judicious use and appropriate utilization of incentives might be an option to motivate potential donors and should be open to discussion.

show abstract

Section: Study and Survey Designmentioning

confidence: 99%

Incentives for Blood Donation: A Discrete Choice Experiment to Analyze Extrinsic Motivation

Sadler

Shi

Bethge

et al. 2018

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…In addition, with the development and approval of anticancer drugs in oral dosage forms over the past few decades (107,108), the number of patients receiving oral anticancer drugs has recently increased (109,110). Therefore, when using these drugs concurrently, drug-drug interactions mediated through P-gp in the small intestine that influence the absorption and pharmacological effects of P-gp substrates given orally is of clinical concern (111,112).…”

Section: Influence Of Alterations In the Expression And Function Of Pmentioning

confidence: 99%

Mechanisms of P-Glycoprotein Alteration During Anticancer Treatment: Role in the Pharmacokinetic and Pharmacological Effects of Various Substrate Drugs

et al. 2014

View full text Add to dashboard Cite

Abstract. In clinical pharmacotherapy, therapeutic benefits and adverse effects of medicines differ substantially between individuals and are often determined by their blood levels. Critical regulators influencing the pharmacokinetics and pharmacodynamics of drugs include drug transporters and drug-metabolizing enzymes. Among these, we have focused on P-glycoprotein (P-gp), a drug efflux transporter. A growing body of evidence indicates that the expression and functional activity of P-gp are altered under several pathological conditions, by exposure to substrate drugs of P-gp, and by ingestion of certain foods. In this critical review, we discuss the mechanisms by which anticancer drugs, most of which are P-gp substrates, alter the expression and functional activity of P-gp in tumors and normal tissues after chronic treatment. Accumulating evidence shows that various transcription factors, in addition to epigenetic and post-translational factors, modulate P-gp expression, which alters the pharmacokinetics and pharmacological effects of drugs. Therefore, it is important to consider individual patients with regard to drug-taking history, as well as levels of P-gp expression and function, when providing clinical pharmacotherapy.Keywords: P-glycoprotein, anticancer drug, drug-drug interaction, opioid, cancer *Corresponding author. stoku@pharm.Kobegakuin.ac.jp Published online in J-STAGE on July 2, 2014 doi: 10.1254/jphs.14R01CRInvited article 243 Changes in P-gp by Anticancer Treatment targeted anticancer drugs acting on specific genes or their products has grown rapidly. In fact, combination treatment with molecularly targeted drugs and cytotoxic chemotherapy against cancers such as acute leukemia or lymphatic malignancy improved therapeutic outcome in comparison to conventional anticancer chemotherapy (8, 9). However, solid tumors often have greater inherent resistance and are less sensitive to anticancer drugs (10). Furthermore, chronic exposure to anticancer drugs frequently leads to multi-drug resistance where the therapeutic effects of these drugs on tumors is largely reduced (11). The development of resistance to anticancer chemotherapy remains one of the major obstacles in effective pharmacological therapy for cancer using current treatment strategies (12).Research revealing the role of drug transporters in cancer began with the discovery of P-glycoprotein (P-gp). In 1976, during research to elucidate the mechanism by which cancer cell lines acquire multi-drug resistance, Juliano et al. discovered that P-gp is over-expressed on the surface membranes of multi-drug resistant cancer cells (13). Subsequent studies have demonstrated that P-gp is present in cancer tissue (11,14), as well as in normal tissues such as small intestine, where it regulates drug absorption, and liver and kidney, where it modulates drug clearance (15). These results suggest that P-gp determines blood levels of its substrate drugs. Furthermore, P-gp is now considered to be an extremely important factor in the pharmacokinetics of drugs bec...

show abstract

“…In the practice of DCEs, respondents are presented with a sequence of choices for alternative options and are asked to select the one they prefer, with each alternative being described by different attributes and attribute levels [6][7][8][9]. A recent review showed a substantial increase in the application of DCEs in health economics and medical decision making and a desire to incorporate patients' and doctors' preferences in the study of effectiveness of treatments [10].…”

Section: Introductionmentioning

confidence: 99%

The Influence of Genotype Information on Psychiatrists’ Treatment Recommendations: More Experienced Clinicians Know Better What to Ignore

et al. 2017

View full text Add to dashboard Cite

Patients’ preferences for treatment outcomes for advanced non-small cell lung cancer: A conjoint analysis

Cited by 122 publications

References 43 publications

Incentives for Blood Donation: A Discrete Choice Experiment to Analyze Extrinsic Motivation

Incentives for Blood Donation: A Discrete Choice Experiment to Analyze Extrinsic Motivation

Mechanisms of P-Glycoprotein Alteration During Anticancer Treatment: Role in the Pharmacokinetic and Pharmacological Effects of Various Substrate Drugs

The Influence of Genotype Information on Psychiatrists’ Treatment Recommendations: More Experienced Clinicians Know Better What to Ignore

Contact Info

Product

Resources

About